Bb5a31f81ClaimThe gut-first hypothesis of Parkinson's disease proposes that alpha-synuclein aggregation initiates in enteric neurons and migrates to the brain via connecting nerve bundlesAgreeDisagree
Bb5a31f81ClaimJames Parkinson described gastrointestinal dysfunction in his 1817 work An Essay on the Shaking PalsyAgreeDisagree
Bb5a31f81ClaimTransplanting fecal microbiota from individuals with Parkinson's disease into germ-free mice induced motor impairments and neuroinflammation not observed with healthy control microbiotaAgreeDisagree
Bb5a31f81ClaimA majority of individuals diagnosed with Parkinson's disease experience constipation years or decades prior to the onset of motor symptomsAgreeDisagree
Bb5a31f81ClaimParkinson's disease causes irreversible neuronal death in brain regions including the substantia nigra pars compactaAgreeDisagree
Bb5a31f81ClaimSelegiline, also known as Deprenyl, is an MAO inhibitor originally approved as a prescription drug for Parkinson's diseaseAgreeDisagree
Bb5a31f81ClaimA pooled analysis of over 160,000 adults showed that walking 7,000 steps daily correlated with 28% fewer physical falls and a 38% lower risk of dementiaAgreeDisagree
Bb5a31f81ClaimThe APOE2 allele is associated with a reduced risk of Alzheimer's disease but an elevated risk of cardiometabolic conditionsAgreeDisagree
Bb5a31f81ClaimApproximately 60% of individuals diagnosed with dementia have comorbid cardiometabolic conditionsAgreeDisagree
Bb5a31f81ClaimBlood-based biomarkers used to evaluate dementia pathology include the amyloid-beta 42/40 ratio, phosphorylated tau 217, neurofilament light chain, and glial fibrillary acidic proteinAgreeDisagree
Bb5a31f81ClaimLimbic-predominant age-related TDP-43 encephalopathy (LATE) produces a distinct pattern of dementia that damages frontal brain regions before affecting memory structuresAgreeDisagree
Bb5a31f81ClaimApproximately 25% of individuals carry one copy of the APOE4 allele, and approximately 6% carry two copiesAgreeDisagree
Bb5a31f81ClaimEast African populations carry a genetic variant near the APOE gene that neutralizes the Alzheimer's disease risk associated with the APOE4 alleleAgreeDisagree
Bb5a31f81ClaimApproximately 2% of Alzheimer's disease cases are caused by deterministic mutations in genes such as presenilin and amyloid precursor proteinAgreeDisagree
Bb5a31f81ClaimPost-mortem autopsies of individuals diagnosed with dementia reveal non-amyloid pathologies, including Lewy bodies composed of alpha-synuclein and TDP-43 protein inclusionsAgreeDisagree
Bb5a31f81ClaimCarrying two copies of the APOE4 allele increases the risk of developing Alzheimer's disease by 9 to 10 timesAgreeDisagree
Bb5a31f81ClaimCarrying a single copy of the APOE4 allele triples an individual's risk of developing Alzheimer's diseaseAgreeDisagree
Bb5a31f81ClaimTissue loss in Alzheimer's disease typically begins in the memory system, spreads to language systems, and eventually affects frontal brain regions involved in planning and decision-makingAgreeDisagree
Bb5a31f81ClaimAfter 70 years of age, the incidence of Alzheimer's disease doubles every five yearsAgreeDisagree